Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3500
- Registration Number
- NCT07038473
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT07007962
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
- Conditions
- Yellow Fever Immunization
- Interventions
- Biological: Yellow fever vaccine (live)Biological: YF vaccine (live)
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 640
- Registration Number
- NCT07002060
- Locations
- 🇺🇸
Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans, Louisiana, United States
🇺🇸Rochester Clinical Research- Site Number : 8400005, Rochester, New York, United States
🇺🇸Velocity Clinical Research - Providence- Site Number : 8400003, East Greenwich, Rhode Island, United States
Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
- Conditions
- Chlamydia Trachomatis
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 81239
- Registration Number
- NCT07002047
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
- Conditions
- Graves' Disease
- Interventions
- Drug: Rilzabrutinib dose 1Drug: Rilzabrutinib dose 2
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06984627
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT06975865
- Locations
- 🇺🇸
Bioresearch Partners- Site Number : 8400005, Hialeah, Florida, United States
🇬🇧Investigational Site Number : 8260002, London, United Kingdom
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT06975722
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal ImmunizationHealthy Volunteers
- Interventions
- Biological: PCV21 vaccineBiological: Vaxneuvance vaccineBiological: Hexyon vaccineBiological: M-M-RvaxPro vaccineBiological: Varivax vaccine
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1080
- Registration Number
- NCT06975878
- Locations
- 🇫🇮
Investigational Site Number : 2460008, Espoo, Finland
🇫🇮Investigational Site Number : 2460003, Kokkola, Finland
🇧🇪Investigational Site Number : 0560004, Alken, Belgium
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
- Conditions
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06968975
- Locations
- 🇺🇸
Investigational Site, Swiftwater, Pennsylvania, United States
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT06958536